- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionLast revisionBoth sides next revision | ||
| home:othertreatments:ergot_alkaloids [11.17.2009] – joyful | home:othertreatments:ergot_alkaloids [11.17.2009] – joyful | ||
|---|---|---|---|
| Line 9: | Line 9: | ||
| * [[http:// | * [[http:// | ||
| + | Of particular concern is the danger of [[http:// | ||
| {{tag>}} | {{tag>}} | ||
| Line 14: | Line 15: | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| EDIT | EDIT | ||
| + | |||
| + | some FDA data on this drug ... [[http:// | ||
| + | |||
| + | ACTIONS | ||
| + | There is no specific evidence which clearly establishes the mechanism by which Hydergine® (ergoloid mesylates) preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency. | ||
| + | |||
| + | PRECAUTIONS | ||
| + | Practitioners are advised that because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing Hydergine® (ergoloid mesylates) preparations. | ||
| + | |||
| + | Interactions with Medicines | ||
| + | Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take. | ||
| + | |||
| + | * Almotriptan | ||
| + | * Azithromycin | ||
| + | * Clarithromycin | ||
| + | * Clotrimazole | ||
| + | * Dirithromycin | ||
| + | * Efavirenz | ||
| + | * Erythromycin | ||
| + | * Fluconazole | ||
| + | * Fluoxetine | ||
| + | * Fluvoxamine | ||
| + | * Fosamprenavir | ||
| + | * Frovatriptan | ||
| + | * Indinavir | ||
| + | * Itraconazole | ||
| + | * Josamycin | ||
| + | * Ketoconazole | ||
| + | * Etc. | ||
| + | |||
| + | Other Medical Problems | ||
| + | The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially: | ||
| + | |||
| + | * Liver disease—Higher blood levels of ergoloid mesylates may occur, increasing the chance of side effects | ||
| + | * Low blood pressure or | ||
| + | * Other mental problems or | ||
| + | * Slow heartbeat—Ergoloid mesylates may make the condition worse | ||
| ===== References ===== | ===== References ===== | ||
home/othertreatments/ergot_alkaloids.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.